Treating seizure with recombinant alkaline phosphatase
AssigneeAlexion Pharmaceuticals, Inc.
InventorsAndre MAROZSAN, Denise DEVORE, Susan LIU-CHEN
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Claims33
(canceled)
A method of treating seizure in a human subject having aberrant levels of at least one alkaline phosphatase substrate selected from pyridoxal 5′-phosphate (PLP), inorganic pyrophosphate (PPi), and phosphoethanolamine (PEA), comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
(canceled)
-8. (canceled)
-12. (canceled)
(canceled)
(canceled)
-24. (canceled)
(canceled)
(canceled)
-34. (canceled)
(canceled)
-40. (canceled)
(canceled)
Dependencies are inferred from the claim text.